Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Atypical fibroxanthoma and pleomorphic dermal sarcoma : Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients. / Ørholt, Mathias; Abebe, Kiya; Rasmussen, Louise E.; Aaberg, Frederik L.; Lindskov, Lærke J.; Schmidt, Grethe; Wagenblast, Anne Lene; Petersen, Michael M.; Loya, Anand C.; Daugaard, Søren; Herly, Mikkel; Jensen, David Hebbelstrup; Vester-Glowinski, Peter.
In: Journal of the American Academy of Dermatology, Vol. 89, No. 6, 2023, p. 1177-1184.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Atypical fibroxanthoma and pleomorphic dermal sarcoma
T2 - Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients
AU - Ørholt, Mathias
AU - Abebe, Kiya
AU - Rasmussen, Louise E.
AU - Aaberg, Frederik L.
AU - Lindskov, Lærke J.
AU - Schmidt, Grethe
AU - Wagenblast, Anne Lene
AU - Petersen, Michael M.
AU - Loya, Anand C.
AU - Daugaard, Søren
AU - Herly, Mikkel
AU - Jensen, David Hebbelstrup
AU - Vester-Glowinski, Peter
N1 - Publisher Copyright: © 2023 American Academy of Dermatology, Inc.
PY - 2023
Y1 - 2023
N2 - Background: The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established. Objective: To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis. Methods: All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS. Results: The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse. Limitations: Risk of misclassification and lack of detailed surgical information. Conclusion: The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.
AB - Background: The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established. Objective: To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis. Methods: All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS. Results: The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse. Limitations: Risk of misclassification and lack of detailed surgical information. Conclusion: The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.
KW - atypical fibroxanthoma
KW - local recurrence
KW - metastasis
KW - pleomorphic dermal sarcoma
KW - prognosis
KW - relapse
KW - risk factors
U2 - 10.1016/j.jaad.2023.08.050
DO - 10.1016/j.jaad.2023.08.050
M3 - Journal article
C2 - 37634740
AN - SCOPUS:85171275135
VL - 89
SP - 1177
EP - 1184
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 6
ER -
ID: 369357725